Comparison of Ivor Lewis esophagectomy and Sweet esophagectomy for the treatment of middle -lower esophageal squamous cell carcinoma

被引:10
|
作者
Feng, Yuan [1 ]
Wu, Nan [1 ]
Yan, Shi [1 ]
Wang, Xing [1 ]
Yang, Yue [1 ]
机构
[1] Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst,Dept Thorac Surg 2, Key Lab Carcinogenesis & Translat Res,Minist Educ, 52 Fucheng Ave, Beijing 100142, Peoples R China
关键词
Esophageal squamous cell carcinoma; Sweet esophagectomy; Ivor Lewis esophagectomy; overall survival (OS); METASTATIC LYMPH-NODES; CERVICAL ESOPHAGOGASTROSTOMY; TRANSTHORACIC ESOPHAGECTOMY; PREDICTS SURVIVAL; NUMBER; LYMPHADENECTOMY; CANCER; DISSECTION; IMPACT; EXTENT;
D O I
10.21037/jtd.2019.07.68
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: For cancer of the middle and/or lower segment of thoracic esophagus, the Ivor Lewis esophagectomy is the mainstream standard surgery, whereas the Sweet procedure is widely used in China. As no consensus has been reached about the choice of different thoracic approaches, we designed this retrospective study to investigate and compare oncological benefits of the two surgical approaches. Methods: After propensity score matching, 150 patients who underwent the Sweet or Ivor Lewis esophagectomy from August 2003 to December 2009 in the Beijing Cancer Hospital were reviewed. We compared the postoperative recovery, nutritional parameters, and survival of the two different surgical approaches. Results: The 5-year overall survival (OS) rate for the whole group was 48.5%, and the 10-year OS rate was 35.6%. The Ivor Lewis group had a longer operation time, longer duration of chest tube drainage, and a larger volume of total thoracic drainage. No significant differences were found between the two groups in terms of the duration of systemic inflammatory response syndrome (SIRS), length of postoperative hospital stay, duration of postoperative nasogastric tube use, incidence of major complications, and nutritional status after the esophagectomy. The OS rates were similar in both groups. Conclusions: The Sweet and Ivor Lewis esophagectomy are both safe and effective. A change of the surgical incision may not be the best way to increase survival, and the choice of surgical procedure should depend on the preference of the thoracic surgeon to secure the safety of the operation.
引用
收藏
页码:3584 / 3592
页数:9
相关论文
共 50 条
  • [31] Overexpression of IFITM3 predicts poor prognosis in stage IIA esophageal squamous cell carcinoma after Ivor Lewis esophagectomy
    Jia, Yang
    Xiao, Zhaohua
    Jiang, Wenpeng
    Chen, Gang
    Wang, Zhou
    [J]. THORACIC CANCER, 2017, 8 (06) : 592 - 599
  • [32] STMN-1 Gene: A Predictor of Survival in Stage IIA Esophageal Squamous Cell Carcinoma After Ivor-Lewis Esophagectomy?
    Javed Akhtar
    Zhou Wang
    Che Yu
    Zhi Ping Zhang
    Ming Ming Bi
    [J]. Annals of Surgical Oncology, 2014, 21 : 315 - 321
  • [33] Robot assisted esophagectomy for esophageal squamous cell carcinoma
    Zhang, Xiaobin
    Su, Yuchen
    Yang, Yu
    Sun, Yifeng
    Ye, Bo
    Guo, Xufeng
    Mao, Teng
    Hua, Rong
    Li, Zhigang
    [J]. JOURNAL OF THORACIC DISEASE, 2018, 10 (06) : 3767 - 3775
  • [34] Comparison of the Oncologic Outcomes for Patients with Middle to Lower Esophageal Squamous Cell Carcinoma Undergoing Surgical Treatment Using the Ivor-Lewis or McKeown Operation
    Park, Seong Yong
    Park, Boram
    Jeon, Yeong Jeong
    Lee, Junghee
    Cho, Jong Ho
    Choi, Yong Soo
    Zo, Jae Il
    Shim, Young Mog
    Kim, Hong Kwan
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2024,
  • [35] Comparison of long-term outcomes of minimally invasive esophagectomy and open esophagectomy for esophageal squamous cell carcinoma
    Fei, Xiuqu
    Liao, Jie
    Wang, Dawei
    Xie, Ning
    Zhou, Guangli
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (07): : 14361 - 14368
  • [36] Comparison of Transthoracic Esophagectomy with Definitive Chemoradiotherapy as Initial Treatment for Patients with Esophageal Squamous Cell Carcinoma Who Could Tolerate Transthoracic Esophagectomy
    Satoru Matsuda
    Yasuhiro Tsubosa
    Masahiro Niihara
    Hiroshi Sato
    Katsushi Takebayashi
    Keisuke Kawamorita
    Keita Mori
    Takahiro Tsushima
    Tomoya Yokota
    Hirofumi Ogawa
    Yusuke Onozawa
    Hirofumi Yasui
    Hiroya Takeuchi
    Yuko Kitagawa
    [J]. Annals of Surgical Oncology, 2015, 22 : 1866 - 1873
  • [37] Comparison of Transthoracic Esophagectomy with Definitive Chemoradiotherapy as Initial Treatment for Patients with Esophageal Squamous Cell Carcinoma Who Could Tolerate Transthoracic Esophagectomy
    Matsuda, Satoru
    Tsubosa, Yasuhiro
    Niihara, Masahiro
    Sato, Hiroshi
    Takebayashi, Katsushi
    Kawamorita, Keisuke
    Mori, Keita
    Tsushima, Takahiro
    Yokota, Tomoya
    Ogawa, Hirofumi
    Onozawa, Yusuke
    Yasui, Hirofumi
    Takeuchi, Hiroya
    Kitagawa, Yuko
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (06) : 1866 - 1873
  • [38] RETRACTION: Comparison of minimally invasive Ivor Lewis esophagectomy and left transthoracic esophagectomy in esophageal squamous cell carcinoma patients: a propensity score-matched analysis (Retraction of Vol 19, art no 500, 2019)
    Wang, Qi
    Wu, Zixiang
    Zhan, Tianwei
    Fang, Shuai
    Zhang, Sai
    Shen, Gang
    Wu, Ming
    [J]. BMC CANCER, 2022, 22 (01)
  • [39] Comparison of definitive chemoradiotherapy and esophagectomy for stage I esophageal squamous cell carcinoma
    Yamamoto, S.
    Ishihara, R.
    Motoori, M.
    Kawaguchi, Y.
    Uedo, N.
    Takeuchi, Y.
    Higashino, K.
    Yano, M.
    Iishi, H.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 12 - 12
  • [40] Comparison of transthoracic esophagectomy with definitive chemoradiotherapy as initial treatment for esophageal squamous cell carcinoma in patients who could tolerate transthoracic esophagectomy
    Matsuda, Satoru
    Tsubosa, Yasuhiro
    Niihara, Masahiro
    Takebayashi, Katsushi
    Kawamorita, Keisuke
    Mori, Keita
    Tsushima, Takahiro
    Yokota, Tomoya
    Ogawa, Hirofumi
    Onozawa, Yusuke
    Yasui, Hirofumi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)